Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma
Status:
Withdrawn
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The study will assess efficacy, safety and tolerability of NVA237 compared to placebo in
patients with poorly controlled asthma over 52 weeks of treatment.